{"id":73039,"date":"2026-10-14T23:38:14","date_gmt":"2026-10-15T03:38:14","guid":{"rendered":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/ubs-weighs-swiss-exit-amid-capital-crackdown-guggenheim-trims-jj-target\/73039\/"},"modified":"2026-10-14T23:38:14","modified_gmt":"2026-10-15T03:38:14","slug":"ubs-weighs-swiss-exit-amid-capital-crackdown-guggenheim-trims-jj-target","status":"publish","type":"post","link":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/ubs-weighs-swiss-exit-amid-capital-crackdown-guggenheim-trims-jj-target\/73039\/","title":{"rendered":"UBS Weighs Swiss Exit Amid Capital Crackdown; Guggenheim Trims J&#038;J Target"},"content":{"rendered":"<h2>Key Takeaways<\/h2>\n<ul>\n<li><strong>UBS Group AG (<a href=\"\/stock\/UBS\">UBS<\/a>) is exploring contingency plans to move its headquarters out of Switzerland<\/strong> if lawmakers implement stricter &quot;too-big-to-fail&quot; capital requirements that could cost the bank up to <strong>$20 billion<\/strong>.<\/li>\n<li><strong>Guggenheim Securities lowered its price target for Johnson &amp; Johnson (<a href=\"\/stock\/JNJ\">JNJ<\/a>) to $281 from $287<\/strong>, despite the healthcare giant beating third-quarter earnings expectations and raising its full-year guidance.<\/li>\n<li><strong>The Swiss government&#39;s proposed rules<\/strong> would require systemically important banks to hold significantly more capital against foreign subsidiaries, a move UBS warns could undermine its global competitiveness.<\/li>\n<li><strong>Johnson &amp; Johnson reported Q3 revenue of $25.4 billion<\/strong>, but the stock faced pressure as analysts adjusted forecasts following a &quot;soft&quot; quarter for its MedTech segment and potential deal dilution.<\/li>\n<\/ul>\n<h2>UBS Considers Relocation Over $20 Billion Capital Threat<\/h2>\n<p>Swiss banking giant UBS Group AG (<a href=\"\/stock\/UBS\">UBS<\/a>) is reportedly drafting contingency plans that include a potential relocation of its global headquarters away from Zurich. According to reports from the <em>Wall Street Journal<\/em>, the bank is responding to aggressive new &quot;too-big-to-fail&quot; regulations being debated by Swiss lawmakers. These rules, spurred by the 2023 rescue of <strong>Credit Suisse<\/strong>, could force UBS to hold an additional <strong>$16 billion to $24 billion<\/strong> in Common Equity Tier 1 (CET1) capital.<\/p>\n<p>The bank is currently evaluating several radical options to mitigate the impact of these regulations. These include <strong>acquiring a major U.S. financial institution<\/strong> to facilitate a move to the United States, merging with a European rival, or even selling itself to a U.S.-based bank. While UBS leadership has expressed a strong preference for remaining in Switzerland, they have warned that the proposed capital hikes are <em>excessive<\/em> and could place the firm at a severe disadvantage compared to Wall Street peers.<\/p>\n<h2>Guggenheim Adjusts J&amp;J Outlook Despite Earnings Beat<\/h2>\n<p>Guggenheim Securities has trimmed its price objective for Johnson &amp; Johnson (<a href=\"\/stock\/JNJ\">JNJ<\/a>) to <strong>$281<\/strong>, down from its previous target of <strong>$287<\/strong>. The adjustment comes on the heels of the company&#39;s third-quarter 2026 earnings report, where it posted adjusted earnings of <strong>$2.59 per share<\/strong>, surpassing the consensus estimate of $2.53. Despite the beat and a subsequent raise in full-year sales guidance to a range of <strong>$101 billion to $101.4 billion<\/strong>, the stock saw a mid-single-digit decline in recent sessions.<\/p>\n<p>The price target cut reflects a more cautious stance on the company&#39;s <strong>MedTech segment<\/strong>, which saw a modest 2.5% growth that trailed some analyst expectations. However, Guggenheim maintained its <strong>Buy rating<\/strong>, citing strong performance in the <strong>Innovative Medicine<\/strong> division. Key drugs like <strong>Tremfya<\/strong> (up 68%) and the oncology portfolio, including <strong>Darzalex<\/strong> and <strong>Carvykti<\/strong>, continue to drive the company&#39;s core growth engine toward its goal of $50 billion in oncology sales by 2030.<\/p>\n<h2>Market Implications and Regulatory Pressure<\/h2>\n<p>The potential departure of UBS from Switzerland would mark a historic shift in the global financial landscape. Analysts note that the bank&#39;s balance sheet is now significantly larger than the entire Swiss economy, creating a political stalemate between regulators seeking stability and a bank seeking to maintain its <em>global scale<\/em>. If UBS formalizes its review of a headquarters move, it could trigger a significant re-evaluation of Swiss &quot;safe haven&quot; status for international capital.<\/p>\n<p>For Johnson &amp; Johnson, the focus shifts to its <strong>December 8 Enterprise Business Review<\/strong>. Investors are looking for clarity on how the company will offset upcoming patent expirations and the impact of recent acquisitions. While the Guggenheim target cut suggests near-term valuation adjustments, the firm&#39;s 64-year streak of dividend increases remains a cornerstone for long-term investors seeking stability in a volatile healthcare sector.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Key Takeaways UBS Group AG (UBS) is exploring contingency plans to move its headquarters out of Switzerland if lawmakers implement [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":50383,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"rank_math_schema_Article":[],"rank_math_focus_keyword":[],"rank_math_description":[],"financial_data_references":[],"stock_symbols_mentioned":[],"footnotes":""},"categories":[5012],"tags":[376,1492,4380,5997,6425,10752,23161],"class_list":["post-73039","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-breaking-news","tag-jnj","tag-ubs","tag-stock-market","tag-pharma","tag-banking-regulation","tag-ubsg","tag-nysejnj"],"_links":{"self":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/posts\/73039","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/comments?post=73039"}],"version-history":[{"count":0,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/posts\/73039\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/media\/50383"}],"wp:attachment":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/media?parent=73039"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/categories?post=73039"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/tags?post=73039"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}